NEW YORK (GenomeWeb) – Biocept said this morning that it received notification yesterday from the Nasdaq that it has regained compliance with the exchange's minimum bid listing requirement.

Nasdaq notified the company last November that it had failed to maintain the required $1 per share minimum bid price, and faced delisting if it did not regain compliance within a 180-day grace period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.